Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Krakow, Poland – 8 November 2018 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, will present a new data from SEL120 program at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. The conference is taking place on November 13-16, 2018 at the Convention Centre Dublin in Dublin, Ireland.

The presentation during the symposium will feature preclinical data from Selvita’s CDK8 inhibitor program SEL120 – potential treatment of acute myeloid and lymphoblastic leukemias. SEL120 is the most advanced, fully-owned oncology program in company’s pipeline, currently in IND-enabling studies.

 

The results will be presented at the following poster session:

Poster Title: “SEL120−34A, a potent and specific inhibitor of CDK8, as a potential treatment of acute myeloid and lymphoblastic leukemias.”
Poster Number: 441
Poster Board Number: PB-104
Session Title: Molecular Targeted Agents – PART II
Session Date and Time: Friday, November 16, 2018, 10:00-14:00

 

“We are pleased to present our most recent research results, which highlight in vitro and in vivo activity of our clinical candidate molecule SEL120 in both AML and ALL as a standalone therapy, but also in combination with other targeted agents in clinical development.” – stated Krzysztof Brzozka, Chief Scientific Officer at Selvita. “SEL120, accompanied by other discovery programs focused on development of personalized anticancer medicines continue to advance Selvita’s Targeted Therapeutics research Platform. We look forward to next clinical and scientific milestones in this platform over the next months.” – he added.

Besides SEL120, Selvita will also present additional data of the program in synthetic lethality area – focused on identification of BRM inhibitors with specific toxicity against SMARCA4-deficient tumors.

 

The results will be presented at the following poster session:

Poster Title: “A high-throughput pharmaceutical screening identifies compounds with specific toxicity against SMARCA4-deficient tumors.”
Poster Number: 198
Poster Board Number: PB-049
Session Title: Drug Screening
Session Date and Time: Wednesday, November 14, 2018, 10:00-17:30

 

The EORTC-NCI-AACR Symposium is hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR). The Symposium brings together academics, scientists and pharmaceutical industry representatives from across the globe to learn the latest innovations in drug development, target selection, and the impact of new discoveries in molecular biology.

 


Selvita Oncology Pipeline

In its internal research and development efforts, Selvita focuses on different dimensions of oncology. The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, licensed to Menarini Group. The second most advanced program is SEL120, the first-in-class small molecule inhibitor of CDK8 with potential use in hematological malignancies, colorectal cancer and breast cancer, currently in IND-enabling studies. In August 2017 Selvita signed a partnering agreement with The Leukemia and Lymphoma Society for preclinical and Phase I clinical development of SEL120 in area of AML, within the Therapy Acceleration Program. Selvita early discovery programs are focused on a number of novel oncology targets in the area of kinase inhibitors, cancer metabolism & immunometabolism and immunooncology.

 

About Selvita

Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the USA (Greater Boston, San Francisco Bay), and in the UK (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).

 

Media contact:

Malgorzata Syjud
Selvita S.A.
malgorzata.syjud@selvita.com
+48 660 797 362

Click to share!: